Downregulation of ApoH has been implicated in non-thrombotic conditions, such as exacerbating fatty liver disease and disrupting gut microbiota homeostasis, pointing to its involvement in metabolic and inflammatory pathways [50]. The gene discussed is APOH; the disease is fatty liver disease.